Thomas Gad | Chairman of the Board, President, Founder, Head of Business Development & Strategy |
Claus Moller | Chief Executive Officer |
Bo Kruse | Chief Financial Officer, Treasurer & Secretary |
Robert Burns | H.C. Wainwright |
David Lebowitz | Morgan Stanley |
Etzer Darout | Guggenheim |
Alec Stranahan | Bank of America |
Anupam Rama | JPMorgan |
Peter Lawson | Barclays |
Good morning and welcome to the Y-mAbs Therapeutics Incorporated Third Quarter 2020 Earnings Conference Call. Today's conference is being recorded.
Let me quickly remind you that the following discussion contains certain statements that are considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Because forward-looking statements involve risks and uncertainties, they're are not guarantees of future performance and actual results, they differ materially from those expressed or implied by these forward-looking statements due to a variety of factors including those risk factors discussed in the company's annual report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the SEC on March 12, 2020, and in the company's subsequently filed SEC reports. At this time, I'd like to turn the conference over to Thomas Gad, the company's Founder, Chairman and President.